Earnings Report: Here’s what to expect from Crispr Therapeutics (NASDAQ:CRSP)


Earnings results for Crispr Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics AG is estimated to report earnings on 10/26/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 9 analysts’ forecasts, the consensus EPS forecast for the quarter is $-1.17. The reported EPS for the same quarter last year was $2.4.

Crispr Therapeutics last released its quarterly earnings data on July 27th, 2020. The reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($0.95) by $0.35. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $19.77 million. Its revenue for the quarter was down 86.2% on a year-over-year basis. Crispr Therapeutics has generated $1.17 earnings per share over the last year and currently has a price-to-earnings ratio of 201.4. Crispr Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, October 26th, 2020 based off prior year’s report dates.

Analyst Opinion on Crispr Therapeutics (NASDAQ:CRSP)

17 Wall Street analysts have issued ratings and price targets for Crispr Therapeutics in the last 12 months. Their average twelve-month price target is $104.25, predicting that the stock has a possible upside of 12.52%. The high price target for CRSP is $140.00 and the low price target for CRSP is $31.00. There are currently 1 sell rating, 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Crispr Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.71, and is based on 13 buy ratings, 3 hold ratings, and 1 sell rating. According to analysts’ consensus price target of $104.25, Crispr Therapeutics has a forecasted upside of 12.5% from its current price of $92.65. Crispr Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Dividend Strength: Crispr Therapeutics (NASDAQ:CRSP)

Crispr Therapeutics does not currently pay a dividend. Crispr Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Crispr Therapeutics (NASDAQ:CRSP)

In the past three months, Crispr Therapeutics insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,064,743.00 in company stock. Only 21.40% of the stock of Crispr Therapeutics is held by insiders. 55.29% of the stock of Crispr Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Crispr Therapeutics (NASDAQ:CRSP

Earnings for Crispr Therapeutics are expected to decrease in the coming year, from ($4.72) to ($4.97) per share. The P/E ratio of Crispr Therapeutics is 201.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 19.68. The P/E ratio of Crispr Therapeutics is 201.41, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.14. Crispr Therapeutics has a P/B Ratio of 5.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here